Severity of Brugada syndrome disease manifestation and risk of new-onset depression or anxiety: a Danish nationwide study
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Severity of Brugada syndrome disease manifestation and risk of new-onset depression or anxiety : a Danish nationwide study. / Jespersen, Camilla H. B.; Kroll, Johanna; Bhardwaj, Priya; Winkel, Bo Gregers; Jacobsen, Peter Karl; Jons, Christian; Haarbo, Jens; Kristensen, Jens; Johansen, Jens Brock; Philbert, Berit T.; Riahi, Sam; Torp-Pedersen, Christian; Kober, Lars; Tfelt-Hansen, Jacob; Weeke, Peter E.
I: Europace, Bind 25, Nr. 5, 2023.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Severity of Brugada syndrome disease manifestation and risk of new-onset depression or anxiety
T2 - a Danish nationwide study
AU - Jespersen, Camilla H. B.
AU - Kroll, Johanna
AU - Bhardwaj, Priya
AU - Winkel, Bo Gregers
AU - Jacobsen, Peter Karl
AU - Jons, Christian
AU - Haarbo, Jens
AU - Kristensen, Jens
AU - Johansen, Jens Brock
AU - Philbert, Berit T.
AU - Riahi, Sam
AU - Torp-Pedersen, Christian
AU - Kober, Lars
AU - Tfelt-Hansen, Jacob
AU - Weeke, Peter E.
PY - 2023
Y1 - 2023
N2 - Aims Reduced psychological health is associated with adverse patient outcomes and higher mortality. We aimed to examine if a Brugada syndrome (BrS) diagnosis and symptomatic disease presentation were associated with an increased risk of new-onset depression or anxiety and all-cause mortality. Methods and results All Danish patients diagnosed with BrS (2006-2018) with no history of psychiatric disease and available for >= 6 months follow-up were identified using nationwide registries and followed for up to 5 years after diagnosis. The development of clinical depression or anxiety was evaluated using the prescription of medication and diagnosis codes. Factors associated with developing new-onset depression or anxiety were determined using a multivariate Cox proportional hazards regression model. Disease manifestation was categorized as symptomatic (aborted cardiac arrest, ventricular tachycardia, or syncope) or asymptomatic/unspecified at diagnosis. A total of 223 patients with BrS and no history of psychiatric disease were identified (72.6% male, median age at diagnosis 46 years, 45.3% symptomatic). Of these, 15.7% (35/223) developed new-onset depression or anxiety after BrS diagnosis (median follow-up 5.0 years). A greater proportion of symptomatic patients developed new-onset depression or anxiety compared with asymptomatic patients [21/101 (20.8%) and 14/122 (11.5%), respectively, P = 0.08]. Symptomatic disease presentation (HR 3.43, 1.46-8.05) and older age (lower vs. upper tertile: HR 4.41, 1.42-13.63) were significantly associated with new-onset depression or anxiety. All-cause mortality in this group of patients treated according to guidelines was low (n = 4, 1.8%); however, 3/4 developed depression or anxiety before death. Conclusion Approximately, one-sixth of patients with BrS developed new-onset depression or anxiety following a diagnosis of BrS. Symptomatic BrS disease manifestation was significantly associated with new-onset depression or anxiety.
AB - Aims Reduced psychological health is associated with adverse patient outcomes and higher mortality. We aimed to examine if a Brugada syndrome (BrS) diagnosis and symptomatic disease presentation were associated with an increased risk of new-onset depression or anxiety and all-cause mortality. Methods and results All Danish patients diagnosed with BrS (2006-2018) with no history of psychiatric disease and available for >= 6 months follow-up were identified using nationwide registries and followed for up to 5 years after diagnosis. The development of clinical depression or anxiety was evaluated using the prescription of medication and diagnosis codes. Factors associated with developing new-onset depression or anxiety were determined using a multivariate Cox proportional hazards regression model. Disease manifestation was categorized as symptomatic (aborted cardiac arrest, ventricular tachycardia, or syncope) or asymptomatic/unspecified at diagnosis. A total of 223 patients with BrS and no history of psychiatric disease were identified (72.6% male, median age at diagnosis 46 years, 45.3% symptomatic). Of these, 15.7% (35/223) developed new-onset depression or anxiety after BrS diagnosis (median follow-up 5.0 years). A greater proportion of symptomatic patients developed new-onset depression or anxiety compared with asymptomatic patients [21/101 (20.8%) and 14/122 (11.5%), respectively, P = 0.08]. Symptomatic disease presentation (HR 3.43, 1.46-8.05) and older age (lower vs. upper tertile: HR 4.41, 1.42-13.63) were significantly associated with new-onset depression or anxiety. All-cause mortality in this group of patients treated according to guidelines was low (n = 4, 1.8%); however, 3/4 developed depression or anxiety before death. Conclusion Approximately, one-sixth of patients with BrS developed new-onset depression or anxiety following a diagnosis of BrS. Symptomatic BrS disease manifestation was significantly associated with new-onset depression or anxiety.
KW - BrS
KW - Arrhythmia
KW - Sudden cardiac death
KW - Psychiatric disease
KW - LONG QT SYNDROME
KW - CARDIOVERTER-DEFIBRILLATORS
KW - HEART-DISEASE
KW - MORTALITY
KW - PREVALENCE
KW - SYMPTOMS
KW - QUALITY
KW - DEATH
KW - ASSOCIATION
KW - PREVENTION
U2 - 10.1093/europace/euad112
DO - 10.1093/europace/euad112
M3 - Journal article
C2 - 37129985
VL - 25
JO - Europace
JF - Europace
SN - 1099-5129
IS - 5
ER -
ID: 346350335